Complete pathologic response after neoadjuvant treatment with vemurafenib for malignant melanoma Orit Kaidar-Person, MD, Ayelet Eran, MD, Gil Bar-Sela, MD Journal of the American Academy of Dermatology Volume 70, Issue 2, Pages e39-e41 (February 2014) DOI: 10.1016/j.jaad.2013.09.052 Copyright © 2014 American Academy of Dermatology, Inc. Terms and Conditions
Fig 1 Melanoma before neoadjuvant vemurafenib treatment. Tru-Cut biopsy from the recurrent skin lesion was positive for melanoma and left an open wound at the site, which required prolonged hospitalization. Journal of the American Academy of Dermatology 2014 70, e39-e41DOI: (10.1016/j.jaad.2013.09.052) Copyright © 2014 American Academy of Dermatology, Inc. Terms and Conditions
Fig 2 Site of prior melanoma, shown in Fig 1, after 8 weeks of treatment with vemurafenib. Journal of the American Academy of Dermatology 2014 70, e39-e41DOI: (10.1016/j.jaad.2013.09.052) Copyright © 2014 American Academy of Dermatology, Inc. Terms and Conditions